Pharmalectin

Pharmalectin is a clinical-stage biotechnology company focused on developing inhaled carbohydrate-based therapies to treat respiratory viral infections. The company's lead candidate, PH-101, is an inhaled formulation of a galectin-3 inhibitor designed to bind to the spike proteins of viruses like SARS-CoV-2 and influenza, preventing viral entry into host cells. By targeting the galectin-binding sites on the respiratory epithelium, Pharmalectin aims to provide a broad-spectrum antiviral approach that is less susceptible to viral mutations. The company has conducted clinical trials to evaluate the safety and efficacy of its inhaled treatments in reducing viral load and improving outcomes for patients with COVID-19.